{"doc_id": "si-2022-0727-reg-1", "parent_doc_id": "si-2022-0727", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 727 of 2022", "title": "of 1972) and for the purpose of giving further effect to Regulation (EC) No.", "year": 2022, "heading": "1. These Regulations may be cited as the European Union (Clinical Trials", "text_raw": "1. These Regulations may be cited as the European Union (Clinical Trials \non Medicinal Products for Human Use) (Principal) (Amendment) Regulations", "text_norm": "1 regulation may cited european union (clinical trial medicinal product human use) (principal) (amendment) regulation", "start_char": 658, "end_char": 806, "source_path": "downloads\\2022\\2022_0729.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16751a5e907aea2dc4eddd523fb4ad5a3e356cfbdb08cbfecfbcda5c15b3c5ac", "cross_refs": []}
{"doc_id": "si-2022-0727-reg-2022", "parent_doc_id": "si-2022-0727", "section_id": "reg-2022", "section_label": "Regulation 2022.", "si_number": "S.I. No. 727 of 2022", "title": "of 1972) and for the purpose of giving further effect to Regulation (EC) No.", "year": 2022, "heading": null, "text_raw": "2022.", "text_norm": "2022", "start_char": 806, "end_char": 814, "source_path": "downloads\\2022\\2022_0729.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16751a5e907aea2dc4eddd523fb4ad5a3e356cfbdb08cbfecfbcda5c15b3c5ac", "cross_refs": []}
{"doc_id": "si-2022-0727-reg-2", "parent_doc_id": "si-2022-0727", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 727 of 2022", "title": "of 1972) and for the purpose of giving further effect to Regulation (EC) No.", "year": 2022, "heading": "2. The European Union (Clinical Trials on Medicinal Products for Human", "text_raw": "2. The European Union (Clinical Trials on Medicinal Products for Human \nUse) (Principal) Regulations 2022 (S.I. No. 99 of 2022) are amended by \ninserting after Regulation 61 the following regulation: \n\n“61A. An application to which Regulation 61(a) applies, and which relates \nto the whole State, shall be made to the National Office and the following \nfees shall be payable by the applicant to the National office: \n\n(a) \n\n(b) \n\nin the case of an application under Regulation 12 of the \nEuropean Communities (Clinical Trials on Medicinal Products \nfor Human Use) Regulations 2004— \n(i) \n€1,500 for commercial trials, or \n(ii) €150 for non-commercial trials, \n\nin connection with each such application, with no fee for each \nadditional trial site to which the application relates; and \n\nin the case of a notification of amendment under Regulations \nthe European Communities (Clinical Trials on \n21(3) of \nMedicinal Products for Human Use) Regulations 2004— \n(i) \n€400 for commercial trials, or \n(ii) €50 for non-commercial trials, \n\nin connection with each such notification.”. \n\nGIVEN under my Official Seal, \n\n23 December, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n1 OJ No. 158, 27.5.2014, p. 1. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 3rd January, 2023. \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[727] 3", "text_norm": "2 european union (clinical trial medicinal product human use) (principal) regulation 2022 (s.i no 99 2022) amended inserting regulation 61 following regulation 61a application regulation 61(a) applies relates whole state shall made national office following fee shall payable applicant national office (a) (b) case application regulation 12 european community (clinical trial medicinal product human use) regulation 2004-- (i) eur1 500 commercial trial (ii) eur150 non-commercial trial connection application fee additional trial site application relates case notification amendment regulation european community (clinical trial 21(3) medicinal product human use) regulation 2004-- (i) eur400 commercial trial (ii) eur50 non-commercial trial connection notification  given official seal 23 december 2022 stephen donnelly minister health 1 oj no 158 27.5.2014 p 1 notice making statutory instrument published iris oifigiuil 3rd january 2023 727 3", "start_char": 814, "end_char": 2166, "source_path": "downloads\\2022\\2022_0729.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16751a5e907aea2dc4eddd523fb4ad5a3e356cfbdb08cbfecfbcda5c15b3c5ac", "cross_refs": []}
{"doc_id": "si-2022-0727-explanatory-note", "parent_doc_id": "si-2022-0727", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 727 of 2022", "title": "of 1972) and for the purpose of giving further effect to Regulation (EC) No.", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the European Union (Clinical Trials on Medicinal \nProducts for Human Use) (Principal) Regulations 2022 to provide for fees \npayable to the National Office in respect of applications coming under the \ntransitional provisions that apply in respect of the repeal of the European \nCommunities (Clinical Trials on Medicinal Products for Human Use) \nRegulations 2004. \n\n \n \n \n \n \n\f4 [727] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 1.50 \n\n(DH-464) 75. 1/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend european union (clinical trial medicinal product human use) (principal) regulation 2022 provide fee payable national office respect application coming transitional provision apply respect repeal european community (clinical trial medicinal product human use) regulation 2004 4 727 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 1.50 (dh-464) 75 1 23 propylon", "start_char": 2166, "end_char": 3173, "source_path": "downloads\\2022\\2022_0729.pdf", "extraction_method": "pdfminer", "checksum": "sha256:16751a5e907aea2dc4eddd523fb4ad5a3e356cfbdb08cbfecfbcda5c15b3c5ac", "cross_refs": []}
